pharmaphorum3d
Pharma M&A rumour mill grinds out Mirati's name again
PRMT5 inhibitor MRTX1719 for MTAP-deleted cancers, and selective SOS1 inhibitor MRTX0902. Last year, the Financial Times also reported that there was interest in a Mirati buyout, citing Merck as ...
pharmaphorum2d
Mirati challenges Amgen with FDA okay for KRAS drug
Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...
C&EN8d
MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design
While performing a high-throughput screen (HTS) that identified the hits that led to the discovery of TNG908 and TNG462, we embarked on a structure-based design effort to switch the mechanism of ...
BMJ8d
Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)
Results The IP-MS analysis, followed by validation in patients with SSc, revealed a significant elevation in anti-PRMT5 antibodies among patients with SSc. These antibodies exhibited robust diagnostic ...